Nasus Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Nasus Pharma Ltd., a foreign private issuer, covers the month of December 2025. The report, dated December 22, 2025, serves to furnish a press release titled "Nasus Pharma CEO Issues 2025 Letter to Shareholders" as Exhibit 99.1.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for the CEO's letter rather than a financial statement.
Material Changes
No material financial changes or comparative period data are disclosed within the body of this Form 6-K. The filing references the attached shareholder letter for further details.
Guidance, Outlook, and Risks
Specific guidance, outlook, management commentary, risks, contingencies, or unusual items are not detailed in the filing text itself. These elements are contained within the furnished Exhibit 99.1 (the CEO's Letter to Shareholders).
Key Facts for Investor Verification
- Verify the contents of Exhibit 99.1, the "2025 Letter to Shareholders," for strategic updates and financial commentary.
- Confirm the company's status as a registrant filing under Form 20-F.
- Note that this filing was signed by Dan Teleman, Chief Executive Officer, on December 22, 2025.